cbd government trialsDecember 15, 2021
Cannabidiol (CBD) products have rapidly entered the UK market in a variety of forms, including food and cosmetics. Laboratories across the UK need to be able to accurately measure the CBD content as well as the controlled cannabinoid content in commercially available products. CBD and cannabinoids have been highlighted as difficult compounds to analyse. The aim of the ring trial was to share and compare methods for quantifying CBD and controlled cannabinoids in food and cosmetics among testing laboratories.
The project has been funded by the Department for Business, Energy & Industrial Strategy (BEIS), the Food Standards Agency (FSA), the Home Office and the Office for Product Safety & Standards (OPSS) and has been carried out in collaboration with Food Standards Scotland (FSS) and the Defence Science and Technology Laboratory (DSTL).
This file may not be suitable for users of assistive technology.
Thirty-four national and international laboratories participated in the ring trial. The results have shown that there is good agreement of results between most laboratories. The data includes instrument types and limits of detection which helped assess the capability of testing laboratories and which will be invaluable information to determine the UK capability in analysing CBD products and controlled cannabinoids.
Request an accessible format.
CBD and controlled cannabinoids – Ring trial report.
For more information about the report or the work of the Government Chemist please contact:
Clinical trials are research investigations in which people volunteer to test new medications and treatments as a means to manage various medical conditions.
There are different types of cannabis, and these can contain over 400 various compounds in the raw form. We need to research cannabis products using known stable active components, so that treatment outcomes can be compared and replicated.
There are 2 schemes under which clinical trials involving therapeutic goods, including medicinal cannabis may be conducted in Australia:
The results of ongoing clinical trials will establish an evidence base for medicinal cannabis and inform future treatment decisions.
There are many claims about the beneficial use of medicinal cannabis products for a wide range of conditions. Most of these claims lack solid scientific backing, because cannabis is an illegal drug and it has been difficult for researchers to run research trials.
The 2 main active components that are the current focus of research are tetrahydrocannabinol (THC) and cannabidiol (CBD). However, there are many other components that may be beneficial and will be the focus of research in the future.
Participants in clinical trials for medicinal cannabis will use pharmaceutical medicinal cannabis products approved by the Therapeutic Goods Administration (TGA) and the relevant Human Research Ethics Committee (HREC).
The current research aims to establish which cannabis compounds and dosage levels are effective, and for which conditions and symptoms.
Research is underway both in Australia and internationally to clinically trial a range of medicinal products, visit the Australian New Zealand Clinical Trials Registry.
Research on medicinal cannabis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.